457628-36-3Relevant academic research and scientific papers
A Unique Synthesis of 5,8-Difluoro-2 H -chromene Using Silicone Oil as a Solvent
Kong, Jianshe,Meng, Tao,Su, Jing
, p. 681 - 683 (2015)
A significantly improved synthesis of 5,8-difluoro-2H-chromene 1 using silicone oil as the reaction solvent is described. The new method eliminated the tedious workup and large quantity of waste produced via conventional methods. To our best knowledge, th
Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines
Palakhachane, Sarinya,Ketkaew, Yuwaporn,Chuaypen, Natthaya,Sirirak, Jitnapa,Boonsombat, Jutatip,Ruchirawat, Somsak,Tangkijvanich, Pisit,Suksamrarn, Apichart,Limpachayaporn, Panupun
, (2021/04/15)
A series of 1,2,3-triazole-containing Sorafenib analogues, in which the aryl urea moiety of Sorafenib (1) was replaced with a 1,2,3-triazole ring linking a substituted phenoxy fragment, were prepared successfully via Huisgen 1,3-dipolar cycloaddition and
Enantio- and Diastereoselective, Complete Hydrogenation of Benzofurans by Cascade Catalysis
Gallagher, Timothy,Glorius, Frank,Hu, Tianjiao,Moock, Daniel,Wagener, Tobias
supporting information, p. 13677 - 13681 (2021/05/10)
We report an enantio- and diastereoselective, complete hydrogenation of multiply substituted benzofurans in a one-pot cascade catalysis. The developed protocol facilitates the controlled installation of up to six new defined stereocenters and produces architecturally complex octahydrobenzofurans, prevalent in many bioactive molecules. A unique match of a chiral homogeneous ruthenium-N-heterocyclic carbene complex and an in situ activated rhodium catalyst from a complex precursor act in sequence to enable the presented process.
BTK Inhibitors and uses thereof
-
Paragraph 0814-0818, (2020/05/02)
The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.
